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Objective: To obtain detailed real-world data on persistence and dosing patterns in the utilisation of the TNF
inhibitors adalimumab, etanercept, and infliximab in rheumatoid arthritis (RA) patients treated in Germany.
Methods: In this retrospective observational study claims data of a major German health insurance fund between
2005 and 2008 were analysed. Patients receiving at least one prescription of adalimumab, etanercept or infliximab
were identified and categorised as “TNF inhibitor naive" or “TNF inhibitor continuing”. For the calculation of TNF
inhibitor persistence a survival analysis with the Kaplan–Meier estimator was used. A Cox regression was used to
analyse, if any relevant factors were influencing persistence. Dosage increase rates were analysed for adalimumab,
etanercept and infliximab. Sensitivity analyses based on variations in gap length were conducted.
Results: A total of 2,201 RA patients were identified. 1,468 of these patients were TNF inhibitor naive patients and
733 were defined as TNF inhibitor continuing patients. There were no significant differences in the treatment
persistence rates between adalimumab, etanercept and infliximab for TNF inhibitor naive and continuing patients.
The persistence rate after three years was 22.47% for adalimumab, 24.27% for etanercept and 21.49% for infliximab
naive patients. For continuing patients, the persistence rate after three years was 32.88% for adalimumab, 30.95%
for etanercept, and 33.90% for infliximab, respectively. Gender, medication and Charlson Comorbidities Index did
not influence the persistence significantly. Dosage increase occurred in 7.3% adalimumab, 1.4% etanercept, and
17.2% infliximab naive patients and 5.8%, 1.1% and 11.9% respectively in the continuing patients.
Conclusions: In this study, there were no significant differences in persistence among adalimumab, etanercept and
infliximab treated patients. Consistent with previous research, there was a higher dose escalation for infliximab than
for the two subcutaneous treatments, adalimumab or etanercept.
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Rheumatoid arthritis (RA) is defined as a systemic
autoimmune disease which is characterised by chronic
progression of joint damage. RA is known as the most
frequent chronic inflammatory disease of the joints. Its
prevalence has been estimated in a range between 0.5%
and 1% for different populations worldwide [1]. From
the economic point of view studies have shown that RA
is associated with a high economic burden [2,3].* Correspondence: sn@ivbl.uni-hannover.de
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in any medium, provided the original work is pThe combination of disease-modifying anti-rheumatic
drugs (DMARDs) and the development of tumor necrosis
factor (TNF) inhibitors have for the first time lead to a
clinical remission of RA and induce a delay or complete
stop of the clinical and radiological progression of the
disease, thus improving the quality of life of many patients
with RA [4]. Therefore, TNF inhibitors comprise an
important part of current treatment recommendations in
Germany and other countries [5-7]. The first TNF inhibi-
tors which have been approved for application in RA
treatment in Germany were adalimumab, etanercept, and
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dosing patterns of TNF inhibitors in Germany. There have
been conducted a number of studies in this field. Carmona
and Gomez-Reino studied TNF inhibitors for different
time periods (one, two and three years) based on a Spanish
population [8]. They report persistence rates of 83% (CI:
81–84), 72% (CI: 71–74) and 65% (CI: 63–67) respectively.
A 5 years follow-up Dutch study reports estimates for the
cumulative persistence of 70% after the first year with a de-
crease of the rate to 45% after the last year [9]. Jobanputra
et al. reported from a pragmatic randomized trial of
adalimumab versus etanercept on the primary endpoint of
treatment discontinuation that no statistical significant
difference on persistence was found although adalimumab
had numerically higher persistence rates after one and two
years of treatment 65.0% (58.3%) for adalimumab vs. 56.7%
(43.3%) for etanercept at week 52 (week 104) [10]. The lon-
gest survey for infliximab is a seven years follow-up study
conducted in Greece [11]. The authors estimate a persist-
ence rate for infliximab after the first year of the treatment
of 83%; they also report a decrease of the rate to 33% after
seven years. For etanercept a persistence rate of 70% was
estimated after the first year of the treatment, and after
four years the rate remained at the level of 60%.
Adalimumab showed a persistence rate of 84%, which
declined to 45% after five years. Cho et al. estimate persist-
ence rates for TNF inhibitors based on a Korean popula-
tion [12]. They report an overall persistence rate of 73% for
the period of twelve months and 61% for 18 months. Par-
ticularly for adalimumab and etanercept for the period of
six months the rates were of 82% and 85% and for twelve
months 73% and 78%, respectively. Another study from
Switzerland indicates that infliximab is associated with
higher overall discontinuation rates compared with adali-
mumab and etanercept, explaining it mainly with an
increased risk of infusion or allergic reactions [13].
There is no strong evidence about persistence and
dosing patterns of adalimumab, etanercept and infliximab
in Germany. Our literature overview resulted only in one
study provided by Zink et al. which analysed the TNF
inhibitor persistence rates for the German health care sys-
tem [14]. They estimate the persistence rate of etanercept
and infliximab after a one year of 69% (CI: 62–75) and
65% (CI: 58–73), respectively. However, they exclude
adalimumab from the analysis justifying this by a later
start of enrolment on the German market. In our study
we provide an analysis of persistence rates as well as for
dosage modifications for all three TNF inhibitors for
Germany. We base our study on claims data provided by
a major health insurance fund in Germany over a four
years observation period. One of the advantages of our
analysis is the consideration of RA patients treated by all
medical professionals [15], compared to Zink et al., who
limit the analysis on patients treated by rheumatologists[14]. Therefore, our data could demonstrate the treatment
patterns of all RA patients, even those who were not
treated continuously by a rheumatologist. Using claims
data for the analysis brings further advantages to our
research. Compared with general clinical studies, claims
data provide a better sampling reflecting real-world treat-
ment patterns and avoids possible selection bias. The
results of our study provide a considerable contribution to
the research of the usage TNF inhibitors for RA treatment
in Germany.Methods
Data source
In order to address the study question we retrieved na-
tionwide claims data for the period from 2005 to 2008.
The dataset contains general individual information on a
per-patient basis e.g. on age and gender as well as
detailed data on diagnostic codes and prescribed medi-
cations including number of drug-packages. Moreover,
the admission and discharge dates for inpatient cases,
delivery and prescription date of medicinal products
such as the frequency and the type of different therapies
are available in the data. However, according to the
German law information on clinical outcomes are not to
be provided in the claims data set. The variables on the
treatment in the dataset are grouped according to the
relevant medical care: outpatient care, inpatient care,
rehabilitation, medications. The study was designed from
the point of view of a major German health insurance
fund with nearly 6.5 million covered lives (DAK) in
2008. Based on this nationwide claims data base all
RA-patients receiving at least one prescription of adali-
mumab, etanercept, or infliximab during the years
2005–2008 were identified.Study population and study design
The identification of the study population was based on
the International classification of diseases, 10th revision
(ICD-10) diagnoses codes and prescription data. All pa-
tients who had at least two secured diagnoses of rheumatic
diseases or diseases of the connective tissue in the out-
patient sector as well as at least one prescription of a TNF
inhibitor during the study period 2005–2008 were initially
included in the study. All included patients needed to be
continuously insured in the specific health insurance fund
between the years 2005–2008. From this initial population
all patients were excluded who were younger than 18 years
of age. Additionally, all patients with at least one diagnosis
of an inflammatory disease like Crohn´s disease as well as
patients without an RA-diagnosis were excluded. The rea-
son for this is that TNF inhibitors can also be prescribed in
other indications which are not in the focus of this study.
In a last step all patients were excluded who had not a
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period (Figure 1).
Patients were categorized as “TNF inhibitor naive" or
“TNF inhibitor continuing”. Naive patients were defined
as individuals with RA who stated in the data no TNF
inhibitor prescription during the baseline period of the
study (January 2005 – June 2005). Continuing patients
are defined as patients who had at least one claim for a
TNF inhibitor during the baseline period and at least
one claim in the follow-up period. For each patient in
the final sample an index event was defined individually
as the date of the first anti-TNF prescription after the
baseline period (Figure 2).
For TNF inhibitor continuing patients all secured diag-
noses in the baseline period (1st and 2nd quarter of 2005)
were included for the analysis of patient characteristics.
For TNF inhibitor naive patients the six months precedingFigure 1 Study population.the index event were defined as the period for the analysis
of patient characteristics and all secured diagnoses of the
first and the second quarter before their index quarter
were included because outpatient diagnosis data were only
available quarterly for Germany. The Bonferroni and
Tukey-Kramer method were used to compare variables
like gender, mean age and Charlson-Index between the
TNF inhibitor patients. The Tukey-Kramer method is a
multiple comparison test and it is used to determine
whether three or more means differ significantly in an
analysis of variance.
We retrieved the data on age at index date, gender,
comorbidities, prescribed medication and other variables
related to the treatment. Inpatient and outpatient data
on diagnosis (ICD-10 codes) were used to measure the
Charlson comorbidity index (CCI), which was defined as
a sum of the weights related to each condition for which
Jul
2005
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Dec 
2007
Dec 
2008
first anti-TNF
prescription
Baseline/washout
period
12 month after index/follow-up
Figure 2 Study period.
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Algorithms for Charlson Comorbidities based on Quan
et al. [16] includes 17 comorbidities (myocardial infarc-
tion, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, chronic pulmonary
disease, rheumatic disease, peptic ulcer disease, mild liver
disease, diabetes without chronic complication, diabetes
with chronic complication, hemiplegia or paraplegia, renal
disease, any malignancy, including lymphoma and leukae-
mia, except malignant neoplasm of skin, moderate or
severe liver disease, metastatic solid tumour, AIDS/HIV).
Analysis of persistence
We define persistence as a period of time during which
the patients receive a particular TNF inhibitor. We calcu-
lated it based on the index date and the date of the break
in the treatment with the medication. Regarding to Wu
et al. a “medication discontinuation” was defined as the
first appearance of a gap in the index medication of more
than 60 days [17]. The observation period ended at 31st
December 2008. This date was set as the censoring date
for the analysis under the condition that the break in the
treatment did not exceed 60 days [17,18]. For adalimumab
and etanercept we assume that discontinuation takes place
when the gap between the perceived end date of a
prescription as per label information (e.g. prescription
date +14 days for a single adalimumab prescription) and
the date of the following prescription was more than
60 days apart. For naive infliximab patients, we distinguish
three possibilities when discontinuation occurs. A discon-
tinuation was assumed when the gap between the first
and the second infusion was a) more than 14 plus 60 days,
b) more than 28 plus 60 days between the second and
third infusion, and c) when the gap between subsequent
infusions was more than 56 plus 60 days. A discontinu-
ation for TNF inhibitor continuing patients was assumed
when the gap between each infusion was more than 56
plus 60 days (for infliximab). Patients with only one pre-
scription of TNF inhibitor were excluded in the analyses.
The ability to switch to another TNF inhibitor could be
a major reason for a high discontinuation rate. Therefore,
we analysed patients who did and who did not switch the
TNF inhibitor during their treatment and measured thediscontinuation rates. This is important to investigate the
impact of switching e.g. due to side effects of the first
medication. In addition, we provide sensitivity analyses
varying the gap length. Therefore, the gap between two
consecutive TNF inhibitor prescriptions was set at 30 and
120 days. This represents 50% and 200% of the 60 day gap
as defined in the basic model. German claims data con-
tains no information about medications prescribed
during inpatient episodes. Therefore, the number of
patients with at least one hospitalization was also
analysed within a sensitivity analysis, as these patients
might have received a TNF inhibitor application dur-
ing that time.
The Kaplan–Meier estimator [19] was used for the calcu-
lation of TNF inhibitor persistence. In general, it estimates
the survival function from life-time data. In other words
the estimator is used to estimate the probability that a par-
ticular event does not occur for a test object in a specific
time interval. In many clinical trials it is often used to
measure the efficacy of an intervention based on the time
until occurrence of a particular event. The overall probabil-
ity of surviving at a given time is represented as a product
of the conditional probabilities [20]. To compare the
curves describing persistence of the three anti-TNFs the
log-rank test was used.
Additionally a Cox regression was used to analyse if
age, gender, persistence, type of TNF inhibitor, or
comorbidities were influencing factors on persistence.
Analysis of dosage increase rates
Adalimumab, etanercept, and infliximab are available in
different administration forms (infusion, finished drug
injection, syringe, and injector) and different dosages.
The recommended dosage for etanercept is 25 mg twice a
week or 50 mg once weekly. Adalimumab is recom-
mended at a dosage of 40 mg every other week. In mono-
therapy some patients who experience a decrease in their
response may benefit from an increase in dose to 40 mg
adalimumab every week. Infliximab is administrated intra-
venously with a recommended dose of 3 mg per kg of
body weight for RA. Additional infusions are administered
two and six weeks after the initial infusion and at eight-
week intervals thereafter. In addition, the dosing can be
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on patient needs or other circumstances.
For every single prescription a specific calculation was
made regarding the time horizon for which the prescrip-
tion should suffice in accordance with the information
given in the label of the prescription. The calculation was
done assuming that the treatment was initiated as per the
recommended dose. For instance a prescription of one
syringe of adalimumab was assumed to last for 14 days.
Since the dosing of infliximab depends on the patient´s
body weight, which was not available in the database, the
dose administered in the third infusion (i.e., associated
with the third claim) was taken as the reference dosage for
the analysis. The percentage of patients prescribed with a
dose of more than the recommended dosage was calcu-
lated based on the approach suggested by Wu et al. [17].
The weekly dosage for each prescription was calculated as:
 Quantity multiplied by 7 and divided by the
prescription gap (for adalimumab)
 Dosage multiplied by quantity multiplied by 7 and
divided by the prescription gap (for etanercept)
 Number of vials multiplied by 7 and divided by the
prescription gap (for infliximab)
A prescription gap was defined as the number of days
between a TNF inhibitor prescription and the subsequent
prescription. The average dosage within the first year of
the treatment was compared with the recommended
dosage (e.g. 0.5 syringes per week for adalimumab). An
increase in dosage was defined as an observed average
weekly dosing that exceeded the recommended dose for
etanercept and adalimumab or the reference dose for
infliximab by at least one third (e.g. an average of more
than 0.66 syringes per week of adalimumab is defined as
increase in dosage).Software and data protection
Data management and statistical analyses were realized
with Microsoft® Access 2007 and Microsoft® Excel 2007.
Additionally IBM SPSS Statistics version 19 and Stata
version 11 were used for specific statistical analyses. The
data available for analysis was in a de-identified form.Results
Study population
A total of 2,201 patients were identified (Figure 1). 1,468
of these patients were defined as TNF inhibitor naive pa-
tients and 733 were defined as TNF inhibitor continuing
patients. Mean age of the TNF inhibitor naive patients
was 58 years (±12.00) with 88% being female. Mean age of
the TNF inhibitor continuing patients was 55 years
(±12.32) with 87% being female (Table 1). No significantdifferences could be observed in the age and gender distri-
bution between subgroups.
The Charlson Comorbidities Index was 1.62 for adali-
mumab naive patients, 1.69 for etanercept naive patients,
and 1.52 for infliximab naive patients. For the TNF Inhibi-
tor continuing patients the Charlson Comorbidities Index
was 1.49 for adalimumab, 1.35 for etanercept, and 1.42 for
infliximab. The Index can range between 0 and 33 with
higher numbers indicating higher comorbidity. Hence,
differences in mean terms as observed in the study popu-
lations do not seem to reflect clinically meaningful differ-
ences in terms of comorbidity. The means of the Charlson
Comorbidities Index are not significantly different from
each other (Tukey–Kramer test, p < 0.05). Table 1 shows
the F-value Tukey–Kramer test and the p-value for the
Bonferroni method.
Persistence
Figure 3 illustrates the Kaplan Meier estimation for TNF
inhibitor naive and continuing patients during the
follow-up period of 3.5 years (42 months). There were
no significant differences in the persistence rates
between adalimumab, etanercept and infliximab for TNF
inhibitor naive patients (adalimumab vs. etanercept:
p = 0.936 etanercept vs. infliximab: p = 0.680; adalimu-
mab vs. infliximab: p = 0.737 performing the log-rank
test). Furthermore, there were no significant differences
for continuing patients (adalimumab vs. etanercept:
p = 0.527; etanercept vs. infliximab: p = 0.565; adalimu-
mab vs. infliximab: p = 0.959 performing the log-rank
test). The persistence rate after one year for naive
patients was 50.96% for etanercept, 49.95% for adalimu-
mab, and 47.95% for infliximab. After two years the per-
sistence rate was 32.19% for adalimumab, 32.81% for
etanercept and 34.05% for infliximab. After year three,
the persistence rate was 22.47% for adalimumab, 24.27%
for etanercept and 21.49% for infliximab. The differences
in persistence are apparently small. This is also shown in
the graphs in the overall figure, which shows the naive
and continuing patients data summed up.
For TNF inhibitor continuing patients the overall per-
sistence rates after 1, 2 and 3 years were 62.10%, 43.87%
and 32.88% for adalimumab; 57.49%, 42.20% and 30.95%
for etanercept; and 66.10%, 44.07% and 33.90% for inflix-
imab, respectively.
Impact of comorbidities and other factors on persistence
of TNF inhibitor therapy
Gender, medication and Charlson Comorbidities Index did
not influence the persistence significantly. No significant
hazard ratios (HR) were obtained in the Cox regression.
For the continuing patients, age has a significant influ-
ence on persistence (p ≤ 0.005). Old age lowered the
risk of discontinuation of TNF inhibitors (HR: 0.990,
Table 1 Number of patients, demographic data and Charlson comorbidities at index
TNF inhibitor naive patients (n = 1,468) TNF inhibitor continuing patients (n = 733) TNF inhibitor total patients (n = 2,201)
Adalimumab
(n = 669)
Etanercept
(n = 628)
Infliximab
(n = 171)
Adalimumab
(n = 248)
Etanercept
(n = 367)
Infliximab
(n = 118)
Adalimumab
(n = 917)
Etanercept
(n = 995)
Infliximab
(n = 289)
Mean age1 57 58 58 56 55 55 56 57 56
Female2, % 88 88 89 87 89 86 88 89 88
Charlson Comorbidities Index1,3 1.62 1.69 1.52 1.49 1.35 1.42 1.58 1.56 1.48
1. Myocardial infarction 1.08% 2.20% 0.61% 0.43% 0.91% 1.89% 0.91% 1.74% 1.11%
2. Congestive heart failure 4.62% 4.06% 3.05% 4.33% 3.66% 1.89% 4.54% 3.92% 2.59%
3. Peripheral vascular disease 4.00% 6.60% 4.88% 3.90% 3.96% 5.66% 3.97% 5.66% 5.19%
4. Cerebrovascular disease 4.46% 3.72% 2.44% 1.73% 2.74% 1.89% 3.75% 3.37% 2.22%
5. Dementia 0.46% 0.34% 0.00% 0.00% 0.00% 0.00% 0.34% 0.22% 0.00%
6. Chronic pulmonary disease 14.46% 14.38% 9.15% 19.91% 14.33% 11.32% 15.89% 14.36% 10.00%
7. Peptic ulcer disease 2.92% 2.20% 2.44% 2.60% 1.83% 5.66% 2.84% 2.07% 3.70%
8. Mild liver disease 9.54% 9.64% 8.54% 8.66% 4.88% 9.43% 9.31% 7.94% 8.89%
9. Diabetes without chronic complication 10.15% 13.54% 9.15% 9.96% 8.54% 9.43% 10.10% 11.75% 9.26%
10. Diabetes with chronic complication 2.31% 4.91% 3.05% 2.16% 2.13% 4.72% 2.27% 3.92% 3.70%
11. Hemiplegia or paraplegia 0.92% 0.68% 0.00% 0.43% 0.61% 0.00% 0.79% 0.65% 0.00%
12. Renal disease 3.85% 4.40% 5.49% 1.73% 4.57% 0.94% 3.29% 4.46% 3.70%
13. Any malignancy. including lymphoma
and leukaemia. except malignant
neoplasm of skin
2.46% 4.23% 3.05% 1.30% 1.83% 2.83% 2.16% 3.37% 2.96%
14. Moderate or severe liver disease 0.00% 0.00% 0.00% 0.00% 0.30% 0.00% 0.00% 0.11% 0.00%
15. Metastatic solid tumour 0.31% 0.17% 0.00% 0.00% 0.00% 0.00% 0.23% 0.11% 0.00%
16. AIDS/HIV 0.00% 0.17% 0.00% 0.43% 0.00% 0.00% 0.11% 0.11% 0.00%
F- and p-values
Mean age Gender Charlson index Mean age Gender Charlson index Mean age Gender Charlson index
Adalimumab vs. etanercept 2.6254 1.000 1.3998 1.679 0.957 2.205 0.7768 1.000 0.5637
Adalimumab vs. infliximab 1.5851 1.000 1.3518 1.455 1.000 0.803 0.1062 1.000 2.0666
Etanercept vs. infliximab 0.1165 1.000 2.2446 0.233 0.825 0.8645 0.4249 1.000 1.7001
Tukey-Kramer Bonferroni Tukey-Kramer Tukey-Kramer Bonferroni Tukey-Kramer Tukey-Kramer Bonferroni Tukey-Kramer
1Tested with Tukey–Kramer test.
2Tested with Bonferroni method.
3Based on ICD-10 Coding Algorithms for Charlson Comorbidities by Quan et al. [16].
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and continuing patients a significant difference in per-
sistence could be observed (HR: 1.296, 95% CI: 1.164-
1.443, p = 0.000). Being a naive patient was associated
with an earlier discontinuation of TNF inhibitors. Fur-
thermore, all HR in Table 2 are close to 1.0, therefore,
the impact is considered to be relatively low.
Overall TNF inhibitor discontinuation and switch analysis
Over the whole observation period the number of patients
with overall TNF inhibitor discontinuation, i.e. patients
who receive no other TNF inhibitor prescription after a
discontinuation of the first choice, is 24.22% in adalimu-
mab naive patients (16.53% in adalimumab continuing
patients), 19.59% in etanercept naive patients (8.17% in
etanercept continuing), and 22.81% in infliximab naive
patients (22.88% in infliximab continuing). When consid-
ering not only the index medication choice but all anti-
TNF prescriptions, the overall per patient discontinuation
rate was 64.51% for TNF inhibitor naive and 70.94% for
TNF inhibitor continuing patients over the entire observa-
tion period.
Dosage increase rates
Exceeding the labelled dosing in the time frame of one
year after the index event in the TNF inhibitor naive pa-
tients occurred in 7.3% of adalimumab, 1.4% of etanercept
and 17.2% of infliximab treated patients. Respective figures
for the TNF inhibitor continuing patients were 5.8% in the
adalimumab group, 1.1% in the etanercept group and
11.9% in the infliximab group. This reflects the current
label of all three TNF inhibitors, as only adalimumab and
infliximab allow for dose increases whereas etanercept has
a stricter regime that cannot be adapted.
Sensitivity analysis
For sensitivity analyses the gap between two consecutive
TNF inhibitor prescriptions was set at 30 and 120 days.
The average persistence rate for 30 days was 10.62% over
all patients in the first year after the index event. The
overall persistence rate was 14.35% for adalimumab naive,
9.30% for adalimumab continuing, 14.49% for etanercept
naive and 10.35% for etanercept continuing patients.
With a gap cap set at 120 days the average persistence
rate was 44.45%. The persistence rate for adalimumab
continuing patients was 45.20%, 48.77% for etanercept
and 37.29% for infliximab. The persistence for TNF inhibi-
tor naive patients was 44.84% for adalimumab, 47.93% for
etanercept and 42.69% for infliximab.
The number of patients with at least one hospitalization
was also analysed within a sensitivity analysis, as these
patients might have received a TNF inhibitor application
during that time. The percentage of patients which had at
least one hospitalization for any reason ranged from72.88% in the infliximab TNF inhibitor continuing
patients to a maximum of 82.51% of the adalimumab TNF
inhibitor naive patients (Table 3). The percentage of
patients with an inpatient stay in hospital related to the
RA-disease ranged from 38.31% of the adalimumab TNF
inhibitor continuing patients to a maximum of 46.18% in
the etanercept TNF inhibitor naive patients. Even if days
of inpatient stays were summed up to the permissible gap
the persistence rate did not change significantly.
Discussion
This study was based on claims data of a major health
insurance fund and evaluated the persistence and the
dosage increase rates of TNF inhibitors in patients with
RA. The strength of this study is that all results are
based on real-world data representing the daily life treat-
ment setting in Germany. In addition our study is the
only study which considered all three TNF inhibitors
(adalimumab, etanercept, and infliximab) over a longer
observation period for Germany. To our knowledge it is
the first approach which analysed persistence and dosing
patterns for all patients independently by which medical
professionals they were treated.
Several studies have evaluated TNF inhibitor persistence
[8-14]. The findings of the current study are consistent
with those of Cho et al. who found that there is no signifi-
cant difference in persistence between etanercept and
adalimumab [12]. Although these results are similar, Cho
et al. show a higher persistence. After 12 month our
results in persistence for continuing patients are quite
similar to those of Jobanputra et al. (adalimumab 67,7%
vs. 65.0% and etanercept 58,9% vs. 56,7%). After the sec-
ond year our persistent decreased to 48,8% (adalimumab)
and 42,8% etanercept whereas the results of Jobanputra
et al. shows a higher persistence for adalimumab (58,3%)
and similar for etanercept 43,3% [10]. Compared to the
results of Carmona and Gomez-Reino, Kievit et al. and
Zink et al. our persistence rates are similar, sometimes a
bit lower than the other results [8,9,11,14]. A possible
explanation for these results may be the gap length. Cho
et al. permit a gap of 14 weeks for the persistent calcula-
tion. The gap of 98 days is considerably higher compared
to the 60 days in our study. Something similar applies to
the studies of Kievit et al. and Du Pan et al.. Both studies
have a higher gap definition (3 months respectively
6 month) and state also a higher persistence after the first
year [9,13]. A few studies do not state a definition of inter-
ruption [8,10,11,14]. That inconsistency may be due to the
database because these studies based on clinical datasets
or register. In this data discontinuation dates were set
externally e.g. from an involved physician.
The higher gap definition could be an explanation for
the founding in differences in the study of Fisher et al..
Moreover the study population was restricted to patients
Figure 3 Kaplan-Meier estimates for TNF inhibitor persistence
over time.
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which includes all patients older than 18 years. They
analysed dosing patterns for all three TNF inhibitors in
the United States with managed care data for four years
[21]. This study found significant differences in the treat-
ment persistence rates between adalimumab, etanercept
and infliximab. In our study, there were no significant dif-
ferences in persistence between the three TNF inhibitors.
Carmona et al. did not analyse differences by medication
but in persistence at one, two, and three years by diagno-
sis. They detected that there was a significantly greater
persistence in spondylarthritis than in RA. The current
study excluded spondylarthritis from the analyses.Given the linear relationship between dosage and
costs, dosage increases in clinical practice may have sig-
nificant cost implications for patients and payers [22]. A
recently published RA treatment algorithm advocates
shortening the dosing interval of adalimumab or increasing
the dose or shortening the dosing interval of infliximab in
patients with an inadequate response prior to switching to
another TNF inhibitor [23]. Therefore, it is important to
understand the dosing regimens used for TNF inhibitors in
clinical practice.
Dosage increase rates identified for adalimumab and
infliximab in the current study were similar to those
reported by other studies. Upward dosage adjustment of
infliximab in patients with RA has been associated with
increases of 30–50% in medication costs in recent stud-
ies [24,25]. For instance, Harrison et al. reported that
among naive and continuing patients, dose increases
from the first to the last prescription were more likely to
occur for infliximab (26% and 24%, respectively) than
adalimumab (10% and 9%, respectively) or etanercept
(1% and 3%, respectively) [22]. In the study of Wu et al.
all treatments had similar dose reduction rates, but
terms of dose-increase rates infliximab had the highest
with 28.3% compared to adalimumab (8.7%) and etaner-
cept (6.9%) from the payer perspective [17]. While etaner-
cept had lower dose escalation rates than adalimumab, this
could probably be explained by labelling which advises
against dose escalation. Berger et al. and Agarwal et al. ana-
lysed only the pattern of infliximab utilization [26,27]. The
mean dose increase by Berger et al. over 12 months was
36%. One-half of study population had their dose of inflixi-
mab increased by equal to or greater than 30% between
the initial and final infusions; one-third had their dose
increased by equal to or greater than 50% [26]. In the study
of Agarwal et al. 126 patients (68.8% of the study popula-
tion) had a treatment escalation (19.8% patients with a
dose increase, 27.8% patients with a decrease in the inter-
val, and 52.4% patients with both) [27]. While etanercept
had lower dose escalation rates than adalimumab, this is
consistent with their labelling which advises against dose
escalation.
All the previous mentioned studies have evaluated
TNF inhibitor dose escalation, but there is no standard
analytic method for the calculation of dose escalation.
This fact could explain most of the differences across
the studies [28,29].
This study has some limitations. Compared to a clinical
trial there is no direct clinical data input (e.g. disease activ-
ity, severity grades of a disease, symptom scores, clinical
test results, quality of life data) as health insurances in
Germany are prohibited by federal law to gain knowledge
of any clinical data from their customers. Furthermore,
there are no clinical outcome data available, so the reason
or impact for the discontinuation or dose increase cannot
Table 2 Cox proportional hazard analysis (95% CI) for persistence of TNF inhibitor
HR naive (n = 1,468) HR continuing (n = 733) HR overall (n = 2,201)
Gender (0: male/1: female) 0.942 (0.780-1.138) 0.937 (0.723-1.215) 0.943 (0.810-1.099)
Age 0.999 (0.994-1.005) 0.990 (0.983-0.997)* 0.996 (0.992-1.000)
Medication (reference category: Infliximab)
Etanercept 0.960 (0.788-1.170) 1.084 (0.850-1.381) 1.001 (0.865-1.175)
Adalimumab 0.956 (0.786-1.163) 1.023 (0.790-1.323) 0.983 (0.842-1.148)
Charlson Comorbidities Index 1.018 (0.968-1.071) 1.055 (0.974-1.143) 1.030 (0.987-1.075)
Naive - - 1.296 (1.164-1.443)**
*p ≤ 0.005.
**p = 0.000.
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remission of the disease, a lack of patient compliance or a
change in therapy due to side effects. German claims data
contains no information about medications administered
during an inpatient episode as hospitals receive no add-
itional payments on top of the respective DRG for the
supply of medications. However, the sensitivity analysis
showed that even if the days of inpatient stays were added
to the permissible gap as per definition in the analysis per-
sistence rates did not change significantly. Another limita-
tion is present for the TNF inhibitor continuing patients.
These patients per definition had at least one TNF inhibi-
tor prescription during the baseline period and at least
one claim in the follow-up period. However, it cannot be
assessed when they initially might have started their TNF
inhibitor therapy before the baseline period and for how
long they already have been on TNF inhibitor medication.
Interpretation of reason for the different persistent and
dosing patterns is challenging because there are no infor-
mation about the disease duration in the claims data. By
law health insurance funds are allowed to save the data for
the insured persons for only maximum of five years.
Therefore, we had only this time period for the observa-
tion and analysis. This is a limitation of our study because
this missing information about disease duration and the
severity grades of a disease could influence the rate of per-
sistence. Another confounding variable could be the side
effects of medication. In the data we do not see the
intolerance to pharmaceutical ingredients or medications,
but this could decrease the rate of persistence. Also the
effects of medication, if one medication has no effect forTable 3 Hospitalization/inpatient treatment
TNF inhibitor naive
Adalimumab
(n = 669)
Eta
(n
Numbers of patients with at least hospitalization for
any reason (%)
522 498
78.03% 79.
Numbers of patients with hospitalization related to RA 298 290
44.54% 46.the patient, as well as preferences of the physician and pa-
tient to one specific medication could influence the rates.
The dosing calculations were based on filed claims
paid by the health insurance. Thus, the results may not
reflect the actual amount of infliximab administrated to
the patient and may over- or underestimate the dosing
for any infusion. For example, a patient that in reality
increased his dosage from 1.2 to 1.8 vials would have
appeared to have a stable dose of two vials if the interval
between infusions remained the same, whereas a patient
increasing from 1.6 to 2.2 vials would have been consid-
ered to move from 2 to 3 vials in terms of claims made
to the health insurance. Furthermore, the present study
did not separate between combination therapy and
monotherapy. We also excluded patients with other
inflammatory disease like Crohn´s disease, because this
indication is treated with TNF inhibitors as well. This
will probably affect the results.
The results of the current study may be generalizable
to other patients with RA, but not be representative of
the entire German population. E.g. the rates of hospital
admissions in this population is very high (up to 82%)
even the persistence rate did not change significantly
although the inpatient stays were summed up to the
allowable gap. One reason could be the population itself.
We did not restrict to high age of the patient. Moreover
the average duration of stays was less than 10 days. So
the rates are very high but the duration is quite short.
Additionally, in context of the results there is no reason
to expect that hospitalisation is disproportionately
distributed among the three study cohorts.patients (n = 1,468) TNF inhibitor continuing patients (n = 733)
nercept
= 628)
Infliximab
(n = 171)
Adalimumab
(n = 248)
Etanercept
(n = 367)
Infliximab
(n = 118)
126 190 278 86
30% 73.68% 76.61% 75.75% 72.88%
66 95 162 47
18% 38.60% 38.31% 44.14% 39.83%
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In summary, the results of this study provide insights
into dosing patterns and persistence of TNF inhibiting
agents for treatment of RA in Germany. The findings
reflect the real-life use of TNF inhibitors without the
limitations of a clinical trial and allow for a head to head
comparison although the inherent limitations of retrospect-
ive claims data analyses do not allow for causal conclusions.
Furthermore, persistence to treatment can improve the
medical outcome and reduce costs. In addition the results
of this paper can be used as input factor for models, for
example in cost-effectiveness analyses.Competing interests
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